[Immunotherapy in the treatment of cancers].
The recent discovery of the molecular structure of tumor antigens expressed by melanoma cells has contributed to the development of therapeutic strategies aimed at stimulating anti-tumor immunity. The first clinical trials in patients with cancer involved systemic administration of interleukin 2 alone or in combination with alpha-interferon or other chemotherapy agents. Objective clinical responses were observed in 15 to 25% of the patients with melanomas or renal cell cancer. In order to improve these encouraging early results, different clinical protocols are being evaluated with the goal of increasing intra-tumoral concentrations of the administered cytokines. Better optimization of methods for immunizing against specific tumor antigens naturally leads to the transition from non-specific stimulation of the human immune system to tumor antigen specific immunotherapy.
Tartour
E
E
Unité d'Immunologie clinique, INSERM U 255, Institut Curie, Paris.
Dorval
T
T
Lee
R S
RS
Fridman
W H
WH
D000818:Animals; D000912:Antibodies, Neoplasm / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D016207:Cytokines / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009374:Neoplasms, Experimental; D014611:Vaccination
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D016207:Cytokines
L'immunothérapie dans le traitement des cancers.